Health
Osimertinib offers a hint of added benefit for NSCLC patients who have received adjuvant chemotherapy – News-Medical.net
Osimertinib was the first drug to be approved for adjuvant treatment after complete tumour resection in adults with stage IB…
Osimertinib was the first drug to be approved for adjuvant treatment after complete tumour resection in adults with stage IB to IIIA non-small cell lung cancer (NSCLC). In an early benefit assessment, the German Institute for Quality and Efficiency in Health…
Continue Reading
-
General15 hours agoCampers evacuated, residents on alert as Moreton Island bushfire intensifies
-
Noosa News21 hours agoPerth Royal Show vendors upset by price hikes, say crowds are down in 2025
-
Business23 hours agoBell Potter names the best ASX shares to buy in October
-
General20 hours agoAustralia welcomes Gaza peace progress, hostage release